Cited by 1,492Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Open access

Tie, Jeanne, Wang, Yuxuan, Tomasetti, Cristian, Li, Lu, Springer, Simeon, Kinde, Isaac, Silliman, Natalie, Tacey, Mark, Wong, Hui-Li, Christie, Michael, Kosmider, Suzanne, Skinner, Iain, Wong, Rachel, Steel, Malcolm, Tran, Ben, Desai, Jayesh, Jones, Ian, Haydon, Andrew, Hayes, Theresa, Price, Tim J., Strausberg, Robert L., Diaz, Luis A., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Gibbs, Peter·2016·Science Translational Medicine

DOI 10.1126/scitranslmed.aaf6219PMC PMC5346159

Open this paper in CoChat — free account

Abstract

Detection of circulating tumor DNA in patients with resected stage II colon cancer provides evidence of residual disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaf6219

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Self-citation
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citation
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Self-citation
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623

Flagged first, then by citations

Show all 43 references

2 of the 43 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

S. Edge D. R. Byrd C. C. Compton A. G. Fritz F. L. Greene A. Trotti AJCC Cancer Staging Manual (Springer New York 2010) 648 pp.

Sorted by citations

Items 201–300 of 1,001

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial
Hu, H., Zhang, J., Li, Y., Wang, X., Wang, Z., Wang, H., Kang, L., Liu, P., Lan, P., Wu, X., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01889 · Cited by 94
Liquid biopsy for cancer: review and implications for the radiologist
Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020) · Radiology · doi:10.1148/radiol.2019182584 · Cited by 87
Circulating Tumor DNA Assays in Clinical Cancer Research
Ossandon, M. R., Agrawal, L., Bernhard, E. J., Conley, B. A., Dey, S. M., Divi, R. L., Guan, P., Lively, T., McKee, T. C., Sorg, B. S., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy105 · Cited by 89
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
Pairawan, S. S., Hess, K. R., Jankú, F., Sánchez, N., Shaw, K. R. M., Eng, C., Damodaran, S., Javle, M. M., Kaseb, A. O., Hong, D. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0306 · Cited by 85
Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication
Hou, J., Li, X., & Xie, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01309-7 · Cited by 86
Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring
Tao, X.-Y., Li, Q., & Zeng, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02063-2 · Cited by 88
The clonal evolution of metastatic colorectal cancer
Dang, H. X., Krasnick, B. A., White, B. S., Grossman, J. G., Strand, M. S., Zhang, J., Cabanski, C. R., Miller, C. A., Fulton, R. S., Goedegebuure, S. P., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9691 · Cited by 83
Enabling Precision Oncology Through Precision Diagnostics
Brown, N. A., & Elenitoba‐Johnson, K. S. J. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012735 · Cited by 84
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
Larribère, L., & Martens, U. M. (2021) · Cancers · doi:10.3390/cancers13225698 · Cited by 80
HPV and head and neck cancers: Towards early diagnosis and prevention
Galati, L., Chiocca, S., Duca, D., Tagliabue, M., Simoens, C., Gheit, T., Arbyn, M., & Tommasino, M. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200245 · Cited by 82
Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer—evaluation in a nationwide Danish cohort
Henriksen, T. V., Demuth, C., Frydendahl, A., Nors, J., Nesic, M., Rasmussen, M. H., Reinert, T., Larsen, O. H., Jaensch, C., Løve, U. S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.009 · Cited by 86
Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker
Lam, W. K., Chan, K. C. A., & Lo, Y. M. D. (2019) · The Journal of Pathology · doi:10.1002/path.5249 · Cited by 80
Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope?
Crigna, A. T., Samec, M., Koklesová, L., Líšková, A., Giordano, F. A., Kubatka, P., & Golubnitschaja, O. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00226-x · Cited by 80
Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth
Gydush, G., Nguyen, E., Bae, J. H., Blewett, T., Rhoades, J., Reed, S. C., Shea, D., Xiong, K., Liu, R., Yu, F., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00855-9 · Cited by 81
Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review
Sario, G. D., Rossella, V., Famulari, E. S., Maurizio, A., Lazarević, D., Giannese, F., & Felici, C. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1152470 · Cited by 88
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy
Deng, X., & Nakamura, Y. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.013 · Cited by 82
Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases
Wang, D., Yang, H., Liu, X., Chen, Z., Wang, Y., Fong, W. P., Hu, M.-T., Zheng, Y.-C., Zheng, Y., Li, B., et al. (2021) · Theranostics · doi:10.7150/thno.59644 · Cited by 80
Self-citation
Cancer Biomarker Discovery for Precision Medicine: New Progress
Zou, J., & Wang, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180718164712 · Cited by 80
Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
Yang, Y., Wang, D., Jin, L., Yao, H., Zhang, J., Wang, J., Zhao, X., Shen, C., Chen, W., Wang, X., et al. (2018) · Bioscience Reports · doi:10.1042/bsr20180322 · Cited by 78
Liquid Biopsy for the Management of Patients with Colorectal Cancer
Yamada, T., Matsuda, A., Koizumi, M., Shinji, S., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Yokoyama, Y., Hara, K., et al. (2018) · Digestion · doi:10.1159/000494411 · Cited by 81
Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account
Kasza, K., Gurnani, P., Hardie, K. R., Cámara, M., & Alexander, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113973 · Cited by 78
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
Tran, H. T., Heeke, S., Sujit, S. J., Vokes, N. I., Zhang, J., Aminu, M., Lam, V. K. L., Vaporciyan, A. A., Swisher, S. G., Godoy, M. C. B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.008 · Cited by 78
Serum biomarker panel for the diagnosis of rheumatoid arthritis
Mun, S., Lee, J., Park, M., Shin, J., Lim, M., & Kang, H. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02405-7 · Cited by 76
The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis
Faulkner, L. G., Howells, L. M., Pepper, C., Shaw, J., & Thomas, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02017-9 · Cited by 79
Clinically Meaningful Use of Blood Tumor Markers in Oncology
Holdenrieder, S., Pagliaro, L. C., Morgenstern, D. E., & Dayyani, F. (2016) · BioMed Research International · doi:10.1155/2016/9795269 · Cited by 84
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Saarenheimo, J., Eigėlienė, N., Andersén, H., Tiirola, M., & Jekunen, A. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00129 · Cited by 76
The Liquid Biopsy in the Management of Colorectal Cancer: An Overview
Vacante, M., Ciuni, R., Basile, F., & Biondi, A. (2020) · Biomedicines · doi:10.3390/biomedicines8090308 · Cited by 75
Integration of Online Omics-Data Resources for Cancer Research
Das, T., Andrieux, G., Ahmed, M., & Chakraborty, S. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578345 · Cited by 77
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer
Cabel, L., Bonneau, C., Bernard‐Tessier, A., Héquet, D., Tran‐Perennou, C., Bataillon, G., Rouzier, R., Féron, J.-G., Fourchotte, V., Brun, J.-F. L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100154 · Cited by 81
The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
Zhang, L., Liang, Y., Li, S., Zeng, F., Meng, Y., Chen, Z., Liu, S., Tao, Y., & Yu, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0989-z · Cited by 76
Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study
Øgaard, N., Reinert, T., Henriksen, T. V., Frydendahl, A., Aagaard, E. M. N., Ørntoft, M. W., Larsen, M. Ø., Knudsen, A. R., Mortensen, F. V., & Andersen, C. L. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.026 · Cited by 72
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
Martínez-Castedo, B., Camblor, D. G., Martín-Arana, J., Carbonell‐Asins, J. A., García-Micó, B., Gambardella, V., Huerta, M., Roselló, S., Roda, D., Gimeno-Valiente, F., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.12.006 · Cited by 79
Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
Jiang, J., Ye, S., Xu, Y., Chang, L., Hu, X., Ru, G., Guo, Y., Yi, X., Yang, L., & Huang, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01220 · Cited by 76
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
Caputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 80
Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review
Fan, G., Zhang, K., Yang, X., Ding, J., Wang, Z., & Li, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171991 · Cited by 71
Vaccination strategies against Zika virus
Fernández, E., & Diamond, M. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.006 · Cited by 75
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer
Schou, J. V., Larsen, F. O., Sørensen, B. S., Abrantes, R., Boysen, A. K., Johansen, J. S., Jensen, B. V., Nielsen, D. L., & Spindler, K.-L. G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx778 · Cited by 72
Clinical indications for, and the future of, circulating tumor cells
Moon, D. H., Lindsay, D. P., Hong, S., & Wang, A. Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.002 · Cited by 73
Electrochemical detection of ctDNA mutation in non-small cell lung cancer based on CRISPR/Cas12a system
Liu, F., Peng, J., Lei, Y., Liu, R., Jin, L. J., Liang, H., Liu, H., Ma, S., Zhang, X., Zhang, Y., et al. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.131807 · Cited by 70
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 77
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring
Mannucci, A., & Goel, A. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02174-w · Cited by 75
Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
Schrock, A. B., Pavlick, D. C., Klempner, S. J., Chung, J., Forcier, B., Welsh, A. W., Young, L., Leyland-Jones, B., Bordoni, R. E., Carvajal, R. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3103 · Cited by 71
Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient’s Stratification
Ginghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 78
Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
Zhu, L., Xu, R., Yang, L., Shi, W., Zhang, Y., Liu, J., Li, X., Zhou, J., & Bing, P. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1172108 · Cited by 72
Liquid Biopsy to Identify Actionable Genomic Alterations
Ou, S. I., Nagasaka, M., & Zhu, V. W. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199765 · Cited by 71
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
Coakley, M. F., García-Murillas, I., & Turner, N. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0152 · Cited by 69
Human TERT promoter mutations as a prognostic biomarker in glioma
Powter, B., Jeffreys, S. A., Sareen, H., Cooper, A. J., Brungs, D., Po, J. W., Roberts, T. L., Koh, E., Scott, K. F., Sajinovic, M., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03536-3 · Cited by 74
Future perspectives of uveal melanoma blood based biomarkers
Beasley, A. B., Chen, F. K., Isaacs, T., & Gray, E. S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01723-8 · Cited by 69
Strategies for improving detection of circulating tumor DNA using next generation sequencing
Tébar-Martínez, R., Martín-Arana, J., Gimeno-Valiente, F., Tarazona, N., Rentero-Garrido, P., & Cervantes, A. M. R. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102595 · Cited by 70
Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches
Perdomo, S. P., Avogbe, P. H., Foll, M., Abedi‐Ardekani, B., Facciolla, V. L., Anantharaman, D., Chopard, P., Calvez‐Kelm, F. L., Vilensky, M., Polesel, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20004 · Cited by 71
Circulating tumour cells and cell-free DNA in gastrointestinal cancer
Pantel, K., & Alix‐Panabières, C. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.198 · Cited by 68
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology
Im, Y. R., Tsui, D. W. Y., Diaz, L. A., & Wan, J. C. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.001 · Cited by 68
Self-citation
Regulatory implications of ctDNA in immuno-oncology for solid tumors
Vellanki, P. J., Ghosh, S., Pathak, A., Fusco, M. J., Bloomquist, E. W., Tang, S. W., Singh, H., Philip, R., Pazdur, R., & Beaver, J. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005344 · Cited by 71
Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
Jin, Z., & Sinicrope, F. A. (2021) · Cancers · doi:10.3390/cancers13020300 · Cited by 67
How to use liquid biopsies to treat patients with cancer
Mattos‐Arruda, L. D., & Siravegna, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100060 · Cited by 70
Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors
Chen, K., Shields, M. D., Chauhan, P. S., Ramirez, R. J., Harris, P. K. W., Reimers, M. A., Zevallos, J. P., Davis, A. A., Pellini, B., & Chaudhuri, A. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00559-x · Cited by 76
ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
Naidoo, M., Gibbs, P., & Tie, J. (2021) · Cancers · doi:10.3390/cancers13020346 · Cited by 67
Self-citation
Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients
Chan, T., Nagayama, S., Otaki, M., Chin, Y. M., Fukunaga, Y., Ueno, M., Nakamura, Y., & Low, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1055968 · Cited by 67
Circulating tumor HPV DNA complements PET‐CT in guiding management after radiotherapy in HPV ‐related squamous cell carcinoma of the head and neck
Tanaka, H., Takemoto, N., Horie, M., Takai, E., Fukusumi, T., Suzuki, M., Eguchi, H., Komukai, S., Tatsumi, M., Isohashi, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33287 · Cited by 65
Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization
Pierik, A. S., Leemans, C. R., & Brakenhoff, R. H. (2021) · Cancers · doi:10.3390/cancers13112635 · Cited by 64
Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing
Hellwig, S., Nix, D. A., Gligorich, K. M., O'Shea, J. M., Thomas, A., Fuertes, C. L., Bhetariya, P., Marth, G., Bronner, M., & Underhill, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197333 · Cited by 57
Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer
Huang, C., Du, M., & Wang, L. (2019) · Cancers · doi:10.3390/cancers11060805 · Cited by 67
The Translational Status of Cancer Liquid Biopsies
Bratulić, S., Gatto, F., & Nielsen, J. (2019) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-019-00141-2 · Cited by 64
Refining Cancer Management Using Integrated Liquid Biopsy
Qiu, J., Xu, J., Zhang, K., Gu, W., Nie, L., Wang, G., & Luo, Y. (2020) · Theranostics · doi:10.7150/thno.40677 · Cited by 63
Clinical application of circulating tumour DNA in colorectal cancer
Loft, M., To, Y. H., Gibbs, P., & Tie, J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00146-2 · Cited by 67
Self-citation
Cell-free DNA fragmentomics in cancer
Tsui, W., Jiang, P., & Lo, Y. M. D. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.006 · Cited by 72
Interplay between P. gingivalis, F. nucleatum and A. actinomycetemcomitans in murine alveolar bone loss, arthritis onset and progression
Ebbers, M., Lübcke, P. M., Volzke, J., Kriebel, K., Hieke, C., Engelmann, R., Lang, H., Kreikemeyer, B., & Müller‐Hilke, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-33129-z · Cited by 62
A Sample-to-Targeted Gene Analysis Biochip for Nanofluidic Manipulation of Solid-Phase Circulating Tumor Nucleic Acid Amplification in Liquid Biopsies
Koo, K. M., Dey, S., & Trau, M. (2018) · ACS Sensors · doi:10.1021/acssensors.8b01011 · Cited by 62
Circulating Tumor DNA–Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies
Dasari, A. N., Grothey, A. F., & Kopetz, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9032 · Cited by 64
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study
Schraa, S. J., van Rooijen, K. L., van der Kruijssen, D. E. W., Alarcon, C. R., Phallen, J. A., Sausen, M., Simmons, J. K., Coupé, V. M. H., van Grevenstein, W. M. U., Elias, S. G., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07252-y · Cited by 63
Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer
McDuff, S. G. R., Hardiman, K. M., Ulintz, P., Parikh, A. R., Zheng, H., Kim, D. W., Lennerz, J. K., Hazar-Rethinam, M. H., Seventer, E. E. V., Fetter, I. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00220 · Cited by 60
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., de Castro, D. G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19212-5 · Cited by 63
Circulating tumor DNA detection: A potential tool for colorectal cancer management (Review)
Li, H., Jing, C., Wu, J., Ni, J., Sha, H., Xu, X., Du, Y., Lou, R., Dong, S., & Feng, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9794 · Cited by 61
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 60
Circulating tumor DNA for prognosis assessment and postoperative management after curative‐intent resection of colorectal liver metastases
Reinert, T., Petersen, L. M. S., Henriksen, T. V., Larsen, M. Ø., Rasmussen, M. H., Johansen, A. F. B., Øgaard, N., Knudsen, M., Nordentoft, I., Vang, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33924 · Cited by 62
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2018) · Oncotarget · doi:10.18632/oncotarget.25404 · Cited by 60
Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer
Kim, Y., Kim, Y.-H., Song, Y., Kim, H., Sim, H. W., Poojan, S., Eom, B. W., Kook, M., Joo, J., & Hong, K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0292-5 · Cited by 60
Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA
Azad, T. D., Jin, M. C., Bernhardt, L. J., & Bettegowda, C. (2020) · Neurosurgical FOCUS · doi:10.3171/2019.9.focus19699 · Cited by 61
Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer
Mitchell, S. M., Ho, T., Brown, G. S., Baker, R. T., THOMAS, M. L., McEvoy, A., Xu, Z., Ross, J. P., Lockett, T. J., Young, G. P., et al. (2016) · Genes · doi:10.3390/genes7120125 · Cited by 59
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery
Ng, S. B. H., Chua, C., Ng, M. C. H., Gan, A., Poon, P. S. Y., Teo, M. C. C., Fu, C. W. P., Leow, W. Q., Lim, K. H., Chung, A. Y. F., et al. (2017) · Scientific Reports · doi:10.1038/srep40737 · Cited by 61
An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection
Ou, C. Y., Vu, T., Grunwald, J. T., Toledano, M., Zimak, J., Toosky, M., Shen, B., Zell, J. A., Gratton, E., Abram, T. J., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc01399c · Cited by 60
Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma
Chen, F., Huang, X., Lv, J., Wen, D., Zhou, G., Lin, L. C., Kou, J., Wu, C., Chen, Y., Zheng, Z., et al. (2020) · Cancer · doi:10.1002/cncr.32770 · Cited by 59
Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA
Liu, W., Li, Y., Tang, Y., Song, Q., Wang, J., Li, N., Chen, S., Shi, J., Wang, S., Li, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103945 · Cited by 58
Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival
Murray, D. H., Symonds, E. L., Young, G. P., Byrne, S. E., Rabbitt, P., Roy, A. C., Cornthwaite, K. J., Karapetis, C. S., & Pedersen, S. K. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2701-x · Cited by 58
Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
Ding, Y., Li, W., Wang, K., Xu, C., Hao, M., & Ding, L. (2020) · BioMed Research International · doi:10.1155/2020/6843180 · Cited by 61
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Paracchini, L., Beltrame, L., Grassi, T., Inglesi, A., Fruscio, R., Landoni, F., Ippolito, D., Marchette, M. D., Paderno, M., Adorni, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3345 · Cited by 57
Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)
Benhaïm, L., Bouché, O., Normand, C., Didelot, A., Mulot, C., Corre, D. L., Garrigou, S., Djadi‐Prat, J., Renault, S., Perez‐Toralla, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.004 · Cited by 61
Ecology and evolution of dormant metastasis
Blasco, M. T., Espuny, I., & Gomis, R. R. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.002 · Cited by 56
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Rustad, E. H., Coward, E., Skytøen, E. R., Misund, K., Holien, T., Standal, T., Børset, M., Beisvåg, V., Myklebost, O., Meza‐Zepeda, L. A., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.160564 · Cited by 58
Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection
Symonds, E. L., Pedersen, S. K., Murray, D. H., Jedi, M., Byrne, S. E., Rabbitt, P., Baker, R. T., Bastin, D., & Young, G. P. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0500-5 · Cited by 61
Heterogeneity in Malignant Pleural Mesothelioma
Oehl, K., Vrugt, B., Opitz, I., & Meerang, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061603 · Cited by 55
Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience
Kothari, P. D., Marass, F., Yang, J. L., Stewart, C. M., Stephens, D. P., Patel, J., Hasan, M., Jing, X., Meng, F., Enriquez, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3144 · Cited by 59
The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
Chakrabarti, S., Xie, H., Urrutia, R. A., & Mahipal, A. (2020) · Cancers · doi:10.3390/cancers12102808 · Cited by 60
Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection
Pantel, K. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002205 · Cited by 56
Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine
Bamodu, O. A., Chung, C., & Pisanic, T. R. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100126 · Cited by 63
Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?
Xu, T., & Gao, H. (2020) · Human Genomics · doi:10.1186/s40246-020-00265-5 · Cited by 55
Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late
IJzerman, M. J., de Boer, J., Azad, A., Degeling, K., Geoghegan, J. M., Hewitt, C., Hollande, F., Lee, B., To, Y. H., Tothill, R. W., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11010103 · Cited by 55
Self-citation
Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis
Zheng, J., Qin, C., Wang, Q., Tian, D., & Chen, Z. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105109 · Cited by 54
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Dorbeau, M., Bazille, C., & Bibeau, F. (2017) · Côlon & Rectum · doi:10.1007/s11725-017-0702-6 · Cited by 58
Cell‐free DNA copy number variations in plasma from colorectal cancer patients
Li, J., Dittmar, R. L., Xia, S., Zhang, H., Du, M., Huang, C., Druliner, B. R., Boardman, L., & Wang, L. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12077 · Cited by 55

Authors: Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., Kosmider, S., Skinner, I., Wong, R., Steel, M., Tran, B., Desai, J., Jones, I., Haydon, A., Hayes, T., Price, T. J., Strausberg, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
Affiliations: The University of Melbourne (AU)
Howard Hughes Medical Institute (US)
Johns Hopkins University (US)
PapGene (United States) (US)
The Royal Melbourne Hospital (AU)
Western Health (AU)
Walter and Eliza Hall Institute of Medical Research (AU)
Eastern Health (AU)
The Alfred Hospital (AU)
Department of Medical Oncology, Warrnambool Hospital, Warrnambool, Victoria 3280, Australia.
Department of Medical Oncology, Queen Elizabeth Hospital and University of Adelaide, Adelaide, South Australia 3174, Australia.
Ludwig Cancer Research (US)
Corresponding author: Tie, Jeanne
Wang, Yuxuan
Vogelstein, Bert
Gibbs, Peter
ORCID: Tie, Jeanne
Wang, Yuxuan
Tomasetti, Cristian
Li, Lu
Springer, Simeon
Silliman, Natalie
Tacey, Mark
Wong, Hui-Li
Christie, Michael
Kosmider, Suzanne
Skinner, Iain
Wong, Rachel
Steel, Malcolm
Tran, Ben
Desai, Jayesh
Jones, Ian
Haydon, Andrew
Hayes, Theresa
Diaz, Luis A.
Papadopoulos, Nickolas
Kinzler, Kenneth W.
Vogelstein, Bert
Gibbs, Peter
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2016-07-06
Volume: 8
Issue: 346
Pages: 346ra92-346ra92
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aaf6219
PMC: PMC5346159
OpenAlex: W2460179076
Cited by: 1,492
References: 43
Citations by year: 2026: 119 · 2025: 131 · 2024: 130 · 2023: 181 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 146 · 2018: 134 · 2017: 90 · 2016: 14
FWCI: 53.29
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.sciencemag.org/about/science-licenses-journal-article-reuse (vor, 365 d)
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders: Virginia and D.K. Ludwig Fund for Cancer Research
Conrad N. Hilton Foundation
Sol Goldman Sequencing Facility at Johns Hopkins
NIH (CA57345, R37-CA43460, U01-CA152753, P30-CA006973)
Victorian Cancer Agency
Victorian Cancer Agency Clinical Research Fellowship
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: circulating tumor DNA, stage II colon cancer, minimal residual disease, tumor recurrence prediction, adjuvant chemotherapy, liquid biopsy, recurrence-free survival, plasma biomarkers, resected colon cancer
MeSH terms: Circulating Tumor DNA, Colonic Neoplasms, Humans, Neoplasm Recurrence, Local, Neoplasm Staging, Prospective Studies, Proportional Hazards Models, Neoplasm, Residual, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks